Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Dense MVAC for Muscle Invasive Bladder Cancer

NCT01031420

Muscle Invasive Bladder Cancer High Risk Urothelial Carcinoma of the Upper Urinary Tracts

COMPLETED PHASE2

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

NCT04383743

Stage II Bladder Cancer AJCC v8 Stage IIIA Bladder Cancer AJCC v8 Muscle Invasive Bladder Carcinoma

COMPLETED PHASE2

Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00003701

Bladder Cancer Urethral Cancer

COMPLETED PHASE3

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082

Bladder Flat Urothelial Carcinoma In Situ Non-Muscle Invasive Bladder Urothelial Carcinoma Stage 0a Bladder Cancer AJCC v8 +2 more

ACTIVE_NOT_RECRUITING PHASE2

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

NCT04579133

Bladder Cancer Urothelial Carcinoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Participants will be given a study infusion schedule for each treatment cycle. Each treatment cycle lasts three weeks. The infusion of methotrexate will take place on the first day of each cycle. Infusions of vinblastine, doxorubicin and cisplatin will take place on the second day and an injection of pegfilgrastim will be given on the third day.
* During all treatment cycles participants will have a physical exam and will be asked questions about their general health and any problems they might be having and any medications they may be taking.
* Following completion of study treatment, but before surgery, participants will have an assessment of their tumor by CT scan of the chest and and MRI of the abdomen and pelvis.
* Following the participants surgery, we would like to keep track of their medical condition indefinitely, or until this study is officially completed. We would like to do this by calling the participants on the telephone once a year to see how they are doing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer Muscle-invasive Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Dense MVAC

Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

intravenously 30mg/m2 over 30 minutes

Doxorubicin

Intervention Type DRUG

intravenously 30mg/ms over 15 minutes

vinblastine

Intervention Type DRUG

intravenously 3mg/m2 over 30 minutes

cisplatin

Intervention Type DRUG

intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion

Pegfilgrastim

Intervention Type DRUG

Given subcutaneously 24 hours after last chemotherapy dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methotrexate

intravenously 30mg/m2 over 30 minutes

Intervention Type DRUG

Doxorubicin

intravenously 30mg/ms over 15 minutes

Intervention Type DRUG

vinblastine

intravenously 3mg/m2 over 30 minutes

Intervention Type DRUG

cisplatin

intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion

Intervention Type DRUG

Pegfilgrastim

Given subcutaneously 24 hours after last chemotherapy dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologic proof of urothelial cancer. Patients with all histologic subtypes are eligible as long as transitional cell carcinoma is predominant, with the exception of more than a few clusters of small cell carcinoma, which is treated with different chemotherapy and thus are ineligible
* Patients with primary tumors arising in the bladder or urethra are eligible if they have clinical T2-T4a disease
* Patients with primary tumors arising in the ureter or renal pelvis are eligible if they have either grade 3 tumors, or radiographic abnormality large enough to be recognized as an abnormal mass by CT/imaging
* Evaluation by a urologist and be deemed to be acceptable surgical candidates within 3 months of registration
* Adequate physiologic reserves as outlined in the protocol
* Clinical or pathologic N1 lymph node involvement (involvement of a single lymph node \< 2cm in greatest dimension) are eligible. Patients with N2-3 or M1 disease are ineligible
* Determination of LV function with an EF \> 50%
* Women of child-bearing potential must have a negative pregnancy test
* Patients of child-bearing or father-bearing potential must agree to use an acceptable form of birth control while on the study
* Patients with prior malignancy are eligible provided that the expected outcome from the prior cancer is such that this will not interfere in the delivery of this therapy, or the assessment of response in the cystectomy specimen
* 18 years of age or older

Exclusion Criteria

* Current, recent (within 3 weeks), or planned participation with other experimental anti-cancer medications as part of clinical trials
* Prior treatment with doxorubicin
* Prior systemic cytoreductive chemotherapy for bladder cancer
* Blood pressure of \> 160/100 mmHg. Patients whose blood pressure can be controlled with oral medication are eligible
* NYHA Grade II or greater congestive heart failure
* History of myocardial infarction or unstable angina within 6 months prior to study enrollment
* History of stroke or transient ischemic attack within 6 months prior to study enrollment
* Clinically significant peripheral vascular disease
* Evidence of bleeding diathesis or coagulopathy
* Known history of central nervous system or brain metastases
* Major surgical procedure, significant traumatic injury within 21 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
* Lactating women
* Patients who are not candidates for surgery, or unwilling to undergo surgery
* Patients with significant fluid collection
* Known hypersensitivity to any component of cisplatin, methotrexate, vinblastine, doxorubicin or pegfilgrastim

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No